Table 2 Results
From: Are the current IHS guidelines for migraine drug trials being followed?
Acute | Prophylaxis | |
|---|---|---|
Mean score of RDB trials | 4.7 (range 2–6) | 5.6 (range 4–9) |
Mean score of all reviewed trials | 4.4 (range 0–6) | 5.1 (range 1–9) |
Percentage of non-RDB trials | 15.2% (22 of 145) | 9.6% (5 of 52) |
Percentage of RDB trials using the recommended primary efficacy measure | 30.9% (38 of 123) | 72.3% (34 of 47) |
Percentage of RDB trials placebo-controlled | 82.9% (102 of 123) | 76.6% (36 of 47) |